Licensing Opportunity: RSV F Proteins and Their Use for Vaccines, Diagnostics, and More

Licensing Opportunity:

RSV F Proteins and Their Use for Vaccines, Diagnostics, and More

Scanning electron micrograph of human respiratory syncytial virus (RSV) virions (colorized blue) and labeled with anti-RSV F protein/gold antibodies (colorized yellow) shedding from the surface of human lung epithelial A549 cells. Credit: NIAID

Researchers from NIAID’s Vaccine Research Center have produced a homogeneous, soluble respiratory syncytial virus (RSV) fusion (F) glycoprotein vaccine that is stabilized in the prefusion conformation and has improved stability and immunogenicity compared to the native protein. Several modifications have removed the requirement for furin during production, resulting in an increase in expression and stability levels of the immunogen. Potential applications of these modified prefusion RSV F proteins include an RSV vaccine for human use, a B cell-sorting probe to isolate potent neutralizing monoclonal antibodies, and a diagnostic to assess the titer of prefusion-specific antibodies in sera.

Read more about this exciting licensing opportunity: https://www.ott.nih.gov/technology/e-064-2016-0.